Pipeline

Wholly-owned Collaboration
Product (Partner)
Phase
Binimetinib* (Ono, Pierre Fabre) Indication: Cancer
Target: MEK
   Phase 3
Encorafenib* (Ono, Pierre Fabre) Indication: Cancer
Target: BRAF
   Phase 3
Selumetinib (AstraZeneca) Indication: Cancer
Target: MEK
   Phase 3
Danoprevir (Roche) Indication: Hepatitis C
Target: NS3 Protease
   Phase 3
Ipatasertib (Genentech) Indication: Cancer
Target: AKT
   Phase 3
Varlitinib (ASLAN) Indication: Cancer
Target: Pan-HER
   Phase 3
ARRY-797 Indication: LMNA-related DCM
Target: p38
   Phase 3
ARRY-382 Indication: Cancer
Target: CSF1R
  Phase 2
Larotrectinib (Loxo Oncology) Indication: Cancer
Target: PanTrk
  Phase 2
Tucatinib (Cascadian Therapeutics) Indication: Cancer
Target: HER-2
  Phase 2
Motolimod (Celgene) Indication: Cancer
Target: TLR
  Phase 2
Prexasertib (Eli Lilly) Indication: Cancer
Target: Chk-1
  Phase 2
GDC-0575 (Genentech) Indication: Cancer
Target: Chk-1
 Phase 1
LOXO-292 (Loxo Oncology) Indication: Cancer
Target: Ret
 Phase 1
LOXO-195 (Loxo Oncology) Indication: Cancer
Target: Trk
 Phase 1

*Wholly owned in the United States and Canada

Continuing Medical Education / Grant Requests
Array BioPharma Guidelines for the Support of Independent Medical Education.pdf
CME@arraybiopharma.com